Resistance of some Candida species to antimycotic agents is a public health threat, with new treatments a priority. Conifer Green Needle Complex (CGNC) is a pharmaceutical-grade complex substance from the green verdure of Pinus sylvestris and Picea abies. Characterization of the chemical composition of CGNC (gas chromatography/mass spectrometry/HPLC) showed resin acids (ca 20 %w/w), unsaponafiables, primarily terpenoid alcohols (ca 22% w/w), higher fatty acids (ca 10% w/w), bound acids (ca 11% w/w) and polyprenols (ca 2.5% w/w). Other significant components include phytosterols, carotenoids, chlorophyll derivatives, vitamin E acetate and vitamin K1. CGNC has high antioxidant activity. Preliminary results for antimycotic activity against clinical strains of Candida albicans, С. glabrata and C. krusei showed some Candida spp. were sensitive to CGNC, including fluconazole-and ketoconazole-resistant strains. Antimycotic activity of CGNC should be investigated in larger studies.
Resistance to antifungals is an emerging threat to public health, with certain species of Candida developing resistance to antifungal drugs such as fluconazole [1] [2] . In the US, approximately 30% of patients hospitalised with a Candida infection in their bloodstream die [3] . Use of azoles (fluconazole or ketoconazole) has resulted in the emergence of azole-resistant Candida spp. [4] including C. glabrata [5] .
Natural products have been used to treat candidiasis [6] and can have antifungal activity against azole-susceptible and azole-resistant Candida spp. [7] [8] [9] .
A conifer needle extract with a highly controlled composition is known in Australia by the Therapeutic Goods Administration (TGA) Australian Approved Name (AAN), Conifer Green Needle Complex (CGNC; also known as Taiga or Bioeffective ® A).
CGNC contains chlorophyll derivatives, carotenoids, vitamins A, E, and K, phytosterols, polyprenols, squalene, resin acids (approximately 20%), essential oils and natural antibiotics (phytoncides). A component of CGNC, diterpene resin acids, has been shown to exhibit antimicrobial and antimycotic activity [10] [11] [12] . CGNC is a strong antioxidant with antimicrobial properties, and it suppresses Helicobacter pylori in vitro and in vivo [13] [14] and Trichomonas vaginalis in vitro [15] .
This study characterizes the chemical composition of CGNC and presents data demonstrating its antioxidant properties. We also present preliminary results of the antimycotic activity of CGNC on clinical strains of C. albicans, C. glabrata and C. krusei from patients, including strains resistant to current treatments.
Typical chromatographic profiles of the acids and neutrals fractions of CGNC are shown in Figure 1 , A and B, respectively. The retention times of the main peaks are: dimethyl pinifolate (the major resin acid peak) approximately 20 minutes ( Figure 1A and Table  S1 ) and isoabienol (the major neutral component peak) approximately 24 minutes ( Figure 1B and Table S2 ).
The identities of all the main peaks were confirmed by matches of their mass spectra with those in published libraries (NIST98 and WILEY275) and for the key resin acids, retention time equivalence with reference standards. The primary components present in CGNC are shown in Table 1 .
The antioxidant capacity of CGNC was determined using the oxygen radical absorbance capacity (ORAC 5.0) assay, which measures the antioxidant capacity of the test substance against five oxygen radicals (peroxyl, hydroxyl, peroxynitrite, superoxide anion and singlet oxygen).
The antioxidant values of a typical batch of CGNC were higher for four of the five oxygen radicals when compared with another antioxidant-rich food, fresh blueberries ( Table 2 ). The peroxyl ORAC value of CGNC was 410 µmole TE/g compared with 68 µmole TE/g for fresh blueberries ( Table 2 ). The hydroxyl ORAC value was 323 µmole TE/g compared with 178 µmole TE/g, the peroxynitrite ORAC value was 12 µmole TE/g compared with 5 µmole TE/g and the super oxide anion ORAC value was 1700 µmole TE/g compared with 125 µmole TE/g ( Table 2 ).
The ORAC values of CGNC were consistently higher when compared with a range of other foods, including blackberries, plums, strawberries, cherries and apples (data not shown). The sensitivity of 30 strains of C. albicans were tested against CGNC (100, 200 and 300 mg/mL), fluconazole (40 μg/disc) and ketoconazole (20 μg/disc) (Table S3 ). Six strains of C. albicans were sensitive to 100 mg/mL CGNC, 19 to 200 mg/mL and 26 to 300 mg/mL, while 14 were sensitive to fluconazole and 16 to ketoconazole (Table 3 , details in Table S3 ). These results show CGNC has the potential to be used as treatment for some clinical strains of C. albicans, especially where the strains are resistant to fluconazole and ketoconazole.
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The sensitivity of 10 clinical strains of C. glabrata were tested against CGNC (100, 200 and 300 mg/mL), fluconazole (40 μg/disc) and ketoconazole (20 μg/disc) (Table S4) . Two strains were sensitive to 100 mg/mL CGNC, five to 200 mg/mL and eight to 300 mg/mL, with two strains sensitive to fluconazole and three to ketoconazole (Table 3 , details in Table S4 ). C. glabrata is more likely to be resistant to azoles such as ketoconazole [4] , therefore CGNC is a potential candidate for treatment of resistant strains.
The sensitivity of nine clinical strains of C. krusei were tested against CGNC (100, 200 and 300 mg/mL), fluconazole (40 μg/disc) and ketoconazole (20 μg/disc) (Table S8 ). Three strains were sensitive to 100 mg/mL CGNC, seven to 200 mg/mL and eight to 300 mg/mL (Table 3 , details in Table S5 ). None of the strains were sensitive to fluconazole but five were sensitive to ketoconazole ( Table 3 , details in Table S5 ). The strains not sensitive to fluconazole may have developed resistance to this azole. Note: Sensitive to CGNC defined as no growth at 100, 200 and 300 mg/mL of CGNC; Sensitive to fluconazole, as determined by measuring the zone of inhibition (defined as  29 mm in diameter); Sensitive to ketoconazole, as determined by measuring the zone of inhibition (defined as  26 mm in diameter).
The results show that CGNC has potential as a treatment for diseases caused by C. krusei, especially as a new treatment is urgently needed, as some strains used in this study are only sensitive to ketoconazole, a drug that has been deregistered in some jurisdictions. As only nine strains were tested in this study, a further experiment with a greater number of C. krusei clinical strains is warranted.
CGNC is a complex mixture that contains a number of compounds (including diterpene resin acids such as abietic and pimaric acids).
Resin acids exhibit antibacterial and antimycotic activity, and may have contributed to the antimycotic activity against Candida spp. observed in this study. The antimicrobial activity of CGNC has also been demonstrated in patients with precancerous gastric lesions associated with H. pylori infection [14] .
This study shows that Candida spp. (C. albicans, C. glabrata and C. krusei) are sensitive to CGNC. The majority of the Candida strains that were resistant to both fluconazole and ketoconazole CGNC characterization, antimycotic activity and Candida Natural Product Communications Vol. 13 (1) 2018 77 were sensitive to at least one concentration of CGNC, thus CGNC should be considered as having the potential as an effective treatment option for resistant strains.
The promising results from the experiments described in this paper warrant investigating the antimycotic activity of CGNC in a larger future study.
Experimental
Patients: Patients were included in the trial if they satisfied the inclusion criteria and gave written informed consent after having the requirements of the trial and the consent process discussed with them during consultation with a clinician. The Ethics Committee of the Pasteur Research Institute, Saint Petersburg approved the study. 
Preparation of Conifer Green Needle Complex (CGNC):
Conifer Green Needle Complex (CGNC) was prepared as follows. Freshly collected, small branches of Pinus sylvestris and Picea abies (L) Karst were milled separately and a cyclone process removed most of the heavier, woody material. A continuous reflux extractor was loaded with a specific blend (55:45 weight ratio of P. sylvestris to P. abies (L) Karst) of mulched green needles, and extracted using a hydrocarbon solvent. The extract was dewaxed using a settlingfiltration based process, prior to removal of the hydrocarbon extractant and most of the extracted essential oils by a multistage steam distillation.
The concentrated, solvent-free extract obtained was subjected to mild saponification using dilute alkali, before the water content and pH was adjusted to within the specification ranges.
The resulting CGNC was a dark-green, almost black, slightly alkaline (pH 8-9), viscous, aqueous-based paste comprising several hundred components. CGNC (as provided by Prenolica Limited, formerly Solagran Limited) is available in Australia, where it is approved by the TGA for use as a therapeutically active ingredient in listed oral and topical medicines.
Gas chromatography: Gas chromatography of the derivatised acids and of the neutrals fractions was performed using a HP-5 MS capillary column (30 m x 0.25 mm i.d) under the following conditions: helium carrier gas at 1 mL/min, injector at 250˚C, flame ionisation detector (FID), and oven programed from 150˚C up to 250˚C at 5˚C/min, then held at 250˚C (for acids run), and 100˚C up to 270˚C at 5˚C/min, then held at 270˚C (for the neutrals run). Injection volumes were 1 µL, and run times were approximately 45 minutes. The concentration of the CGNC solution was 1000 mg/mL. CGNC was provided as a sterile substance and diluted in sterile, distilled water at 56 ˚С. This initial solution was diluted to concentrations of 100, 200 and 300 mg/mL, which were then used in the experiments with Candida spp. The dose range of CGNC that was chosen for this study is within the physiological range that can be given to humans (data not shown).
In the Candida experiments, fluconazole and ketoconazole were used as comparator drugs. Fluconazole and ketoconazole were sorbed on filter paper discs (manufactured at the Saint Petersburg Pharmacotherapy Research Centre) at 40 μg/disc and 20 μg/disc respectively.
DNA extraction and real-time PCR:
Identification of Candida spp. was as follows. Total DNA was isolated from clinical samples using the DNA-sorb-AM nucleic acid extraction kit (AmpliSens ® , Moscow, Russia) as per the manufacturer's instructions. Real-Time PCR (RT-PCR) was carried out using the AmpliSens ® C. albicans/C. glabrata/C. krusei-MULTIPRIME-FRT PCR kit (AmpliSens ® , Moscow, Russia) and the Rotor Gene 6000 RealTime PCR machine (Corbett, Australia), as per the instruction kit and user manual.
Preparation of microorganisms:
Thirty strains of C. albicans, 10 strains of C. glabrata and nine strains of C. krusei were isolated from patients.
An initial inoculum of 10 3 colony-forming units (CFU)/mL of each Candida strain was prepared for use in the experiments comparing the antimycotic susceptibility of CGNC with fluconazole and ketoconazole.
Sensitivity of Candida spp. to CGNC: An inoculum of Candida (10 3 CFU/ml) was spread on Sabourand dextrose agar plates containing 100, 200 or 300 mg/mL of CGNC. Plates were incubated for 24 hours at 30˚C. After incubation, the number of colonies growing on the surface of the agar plate were counted and recorded.
Disk diffusion tests for fluconazole and ketoconazole:
The surface of Sabourand dextrose agar plates was inoculated with 100 μl of each Candida strain and allowed to dry. Discs impregnated with fluconazole (40 μg/disc) or ketoconazole (20 μg/disc) were placed in the middle of the agar surface and the plates were incubated for 48 hours at 25˚C.
The plates were removed from the incubator and examined for the presence of a zone of inhibition. The diameter of the zone of inhibition, including the diameter of the disk was measured using a ruler. The zone of inhibition was reported in millimetres and the results recorded as sensitive (S), intermediate (I) or resistant (R).
